177 related articles for article (PubMed ID: 30171991)
1. Ovarian neuroendocrine carcinoma of metastatic origin: clues for diagnosis.
Karpathiou G; Matias-Guiu X; Mobarki M; Vermesch C; Stachowicz ML; Chauleur C; Peoc'h M
Hum Pathol; 2019 Mar; 85():309-312. PubMed ID: 30171991
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
3. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
[TBL] [Abstract][Full Text] [Related]
4. Pituitary metastasis of an unknown neuroendocrine breast carcinoma mimicking a pituitary adenoma.
Senetta R; Castellano I; Garbossa D; Sapino A; Cassoni P
Pathology; 2013 Jun; 45(4):422-4. PubMed ID: 23635818
[No Abstract] [Full Text] [Related]
5. Neuroendocrine Tumors of the Breast.
Rosen LE; Gattuso P
Arch Pathol Lab Med; 2017 Nov; 141(11):1577-1581. PubMed ID: 29072945
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
[No Abstract] [Full Text] [Related]
8. CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls.
Ohishi Y; Kaku T; Oya M; Kobayashi H; Wake N; Tsuneyoshi M
Gynecol Oncol; 2007 Oct; 107(1):30-8. PubMed ID: 17583777
[TBL] [Abstract][Full Text] [Related]
9. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
10. Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus.
Shopov ST; Anavi BL; Krastev DK
Folia Med (Plovdiv); 2020 Jun; 62(2):412-417. PubMed ID: 32666759
[TBL] [Abstract][Full Text] [Related]
11. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
12. Primary pure large-cell neuroendocrine carcinoma of the ovary.
Dundr P; Fischerová D; Povýsil C; Cibula D
Pathol Res Pract; 2008; 204(2):133-7. PubMed ID: 18164557
[TBL] [Abstract][Full Text] [Related]
13. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
14. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Differentiation in Thymic Carcinomas: A Diagnostic Pitfall: An Immunohistochemical Analysis of 27 Cases.
Weissferdt A; Moran CA
Am J Clin Pathol; 2016 Mar; 145(3):393-400. PubMed ID: 27124922
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
[TBL] [Abstract][Full Text] [Related]
17. Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors.
Kővári B; Turkevi-Nagy S; Báthori Á; Fekete Z; Krenács L
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059362
[TBL] [Abstract][Full Text] [Related]
18. [Breast carcinoma with predominant neuroendocrine differentiation].
Frachon S; Pasquier D; Treilleux I; Seigneurin D; Ringeisen F; Rosier P; Bolla M; Boutonnat J
Ann Pathol; 2004 Jun; 24(3):278-83. PubMed ID: 15480266
[TBL] [Abstract][Full Text] [Related]
19. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].
Zhang XH; Lu XL; Wu N; Liu B; Wang FY; Zhang RS; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):191-6. PubMed ID: 23769440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
